Health tech platform Qure.ai has secured USD 40 million in a funding round led by Novo Holdings and HealthQuad, supported by existing investor MassMutual Ventures. Qure.ai will use the fresh capital to extend and strengthen its global reach, especially in the US and Europe, and intensify product development for critical care and community diagnostics. 

Qure.ai has created a niche for itself with advanced technology that reads and interprets medical images like X-rays, CTs, and ultrasounds in less than a minute, making equitable and high-quality healthcare a reality across the globe. Qure’s AI solutions are FDA-approved, CE-certified, and evaluated by the World Health Organization.

Qure.ai‘s automated medical imaging tools can shorten the time to diagnosis while enabling physicians to triage medical cases more effectively, especially in time-sensitive situations. This helps healthcare providers identify critical scenarios within minutes — versus hours — to avert fatalities and improve the quality of patient care. In other settings, where adequate, skilled specialists may not be available, Qure’s technology is used as the first level of screening for many infections and non-communicable conditions.
“We are thrilled to be part of the Qure team. Their world-class AI technologies adhere to the most stringent international standards and have made high-quality, accessible care a reality. We remain committed to collaborating with innovative firms that work to improve global healthcare infrastructures,”said Charles – Antoine Janssen, Chief Investment Officer, HealthQuad.